PARP Inhibitor Biomarkers Market
PARPs are enzymes that catalyze the synthesis of poly (ADP-ribose). There are 17 enzymes in this family that transport chains of ADP-ribose to their intended targets. Inhibition of poly (ADP-ribose) polymerase (PARP) is essential for repairing single-strand DNA. Single-strand DNA breaks are expected to cause double-strand DNA breaks during DNA replication, trapping PARP inhibitors at the break sites. Homologous recombination repair (HRR) is a intricate process involving numerous proteins, including BRCA1 and BRCA2 that are also known as biomarkers of PARP inhibitors, and would usually repair the double-strand DNA breaks.
The Global PARP Inhibitor Biomarkers Market is estimated to be valued at US$ 907.1 million in 2023 and is expected to exhibit a CAGR of 24.9% during the forecast period (2023-2030).
Ask Us to Get Your Sample Copy Of The Report, Covering TOC and Regional Analysis @
https://www.coherentmarketinsights.com/insight/request-sample/3762
Key Players
In the global market for PARP inhibitor biomarkers, prominent companies include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc.
Throughout the projected time, the worldwide PARP inhibitor biomarkers market is anticipated to expand because to the rising incidence of cancer around the world.
Cancer is a group of long-lasting diseases defined by unchecked cell proliferation. A report published in 2013 by the National Cancer Institute said that over a hundred distinct types of cancer can be classified based on the cells from which they originate.
Cancer is another main cause of illness and death worldwide, accounting to see an expected 9.6 million deaths in 2018, as per the World Health Organization’s 2018 report. The same source estimates that roughly 1 in every 6 deaths worldwide are caused by cancer.
In 2017, second position was held by cancer being the cause of mortality in the United States, accounting for almost one in four fatalities. This is according to the American Cancer Society.
Market expansion is anticipated to be led by an increase in the prevalence of cancer in breast and ovaries throughout the predicted period. According to the 2018 report from the Global Cancer Research Fund International, for example, breast cancer accounted for 2,088,849 novel cases worldwide in 2018.
The American Cancer Society reports that in 2018, there were a projected 266,120 novel instances of invasive breast cancer identified in women in the United States.
The global market for PARP inhibitor biomarkers is predicted to expand at a moderate rate, but the high price of test kits and assays would likely slow the industry’s expansion. For example, Myriad Genetics, Inc.’s myChoice CDx (recommended retail price: $4,040) entered the market in October 2019. myChoice CDx detects BRCA1 and BRCA2 and is the maiden and only tumor test approved by the FDA for determining homologous recombination deficient status.
PARP Inhibitor Biomarkers Market Report Coverage
| The market size value in 2023 |
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐔𝐩 𝐓𝐨 𝟐𝟓% 𝐎𝐅𝐅 @
https://www.coherentmarketinsights.com/insight/buy-now/3762
Throughout the predicted time period, market expansion will be spurred by an uptick in product approvals.
Use of PARP inhibitors biomarkers can be further facilitated by taking advantage of unexploited markets in developing economies through advantageous pharmaceutical price and new product consents.
For people with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer that has spread due to a BRCA mutation, AstraZeneca and Merck received approval from Health Canada to offer Lynparza as a single maintenance medication in May of this year.
Myriad Genomics, Inc.’s subsidiary, Myriad Genetic Laboratories, Inc., gained approval from the Japanese Ministry of Health, Labour, and Welfare in April 2018 to manufacture and commercialize the BRACAnalysis Diagnostic System as a companion diagnostic for the PARP inhibitor Lynparza.
Table of Contents with Major Points:
Executive Summary
- Introduction
- Key Findings
- Recommendations
- Definitions and Assumptions
Executive Summary
Market Overview
- Definition of PARP Inhibitor Biomarkers Market Market
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Trends and Developments
Key Insights
- Key Emerging Trends
- Key Developments Mergers and Acquisition
- New Product Launches and Collaboration
- Partnership and Joint Venture
- Latest Technological Advancements
- Insights on Regulatory Scenario
- Porters Five Forces Analysis
Qualitative Insights Impact of COVID-19 on Global PARP Inhibitor Biomarkers Market Market
- Supply Chain Challenges
- Steps taken by Government/Companies to overcome this impact
- Potential opportunities due to COVID-19 outbreak
Conclusion
Appendix
- Data Sources
- Abbreviations
- Disclaimer
TOC Continued…!
Ask For Discount Before Purchasing This Business Report :
https://www.coherentmarketinsights.com/insight/request-discount/3762
Why Choose Coherent Market Insights?
☛ Identified business opportunities – Our market research report can be used to analyze potential markets and new products. It can give information about customer needs, preferences, and attitudes. Also, it compare products and services.
☛ A clear understanding of your customers – A market report gives company’s marketing department an in-depth picture about customers’ needs and wants. This knowledge can be used to improve products, prices, and advertising.
☛ Clear data-driven insights – Our Market research encompasses a wide range of activities, from determining market size and segment to forecasting demand, and from identifying competitors to monitoring pricing. All of these are quantified and measurable which means that gives you a clear path for building unique decisions based on numbers.
Explore More Related Insights:
Continuous Glucose Monitoring (CGM) Devices Market
Digital Wound Measurement Devices Market
Single Cell Genome Sequencing Market
Middle East and Asia Pacific Cell and Gene Therapy Market
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Mr. Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837